BAMS
SGNT

Bellevue Asset Management (Switzerland)’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-100,000
Closed -$2.33M – 150
2015
Q1 		$2.33M Buy
+100,000
New +$2.65M 0.32% 75

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s SGNT Position: Q2 2015 in Review

Bellevue Asset Management (Switzerland) sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2015, closing a stake of 100,000 shares — an estimated $2.33M sold.

Bellevue Asset Management (Switzerland) first reported a position in SGNT in Q1 2015 and held it in 1 quarter. The position peaked at $2.33M in Q1 2015. 136 funds tracked by Wall St. Rank hold SGNT as of Q2 2015.

  • Bellevue Asset Management (Switzerland) reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Bellevue Asset Management (Switzerland) sold 100,000 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2015, an estimated $2.33M.
  • Bellevue Asset Management (Switzerland) first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q1 2015 and held it in 1 quarter.
  • Bellevue Asset Management (Switzerland)'s SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $2.33M in Q1 2015.
  • 136 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q2 2015, filed 12 Aug 2015.